Triple-Negative Breast Cancer First-Line Advances

Dr. Kang describes ASCENT-04 results as logical and practice-changing for PD-L1-positive metastatic TNBC. The combination of SG with pembrolizumab compared to standard chemotherapy plus pembrolizumab demonstrated improved PFS in first-line treatment. This approach proves particularly valuable for patients progressing after early-stage therapy who received multi-agent chemotherapy with pembrolizumab per KEYNOTE-522, though benefits extend to treatment-naïve patients despite potentially reduced magnitude in subgroup analyses.

Dr. Kruse emphasizes widespread adoption without insurance barriers, representing a straightforward practice change given familiarity with both agents and their toxicity profiles. The data align with expectations that ADCs are replacing cytotoxic therapy, providing confidence when treating scared patients facing first-line triple-negative disease. The approach follows the principle of using optimal therapy first-line due to potential attrition in subsequent treatment lines, ensuring patients receive maximum PFS benefit.

The speakers note that reality meets expectations regarding ADC superiority over standard chemotherapy, enabling more confident patient discussions about meaningfully improved cancer control and length of life. Implementation requires minimal mental energy given established experience with these agents, making this transition seamless compared to more complex treatment decisions requiring extensive deliberation about sequencing and toxicity management across multiple novel agents with distinct side effect profiles.